Printer Friendly

QUIDEL LAUNCHES NEW C3a ENZYME IMMUNOASSAY

 SAN DIEGO, April 20 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL) today announced the introduction of its new complement C3a enzyme immunoassay in the United States. C3a is another in a group of complement split protein (CSP) tests from QUIDEL and is the only commercially available enzyme immunoassay for C3a in the United States.
 QUIDEL believes that its (CSP) product line sold to laboratories may be useful in predicting the onset of the periodic and intensified disease activity that occurs in autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The use of drug therapy at an earlier stage or prior to the disease "flare" may have the important effect of reducing drug therapy requirements and improving the long-term prognosis of these patients.
 The complement system plays an integral role in the human immune system and is responsible for initiating a series of biological activities crucial for resisting microbial infection. C3a is a activation fragment of the plasma complement protein C3 and is known to cause an acute inflammatory response. The inappropriate activation of complement in autoimmune diseases is believed to contribute importantly to the disease progression.
 Recent research studies have suggested that complement activation may play a role not only in autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus but also Alzheimer's disease, septic shock and adult respiratory distress syndrome. C3a may serve as an additional specific marker for complement activation, similar to the company's existing four complement split protein research assays.
 "The addition of this new C3a test kit rounds out our line of CSP tests and further solidifies QUIDEL's position as one of the world's leading developers and suppliers of complement testing products," said Scott L. Glenn, chairman and chief executive officer at QUIDEL. "Arthritis and lupus researchers throughout the world are presently evaluating the potential utility of C3a as a disease marker. We believe, as most recently suggested in the journal of Arthritis & Rheumatism, our family of complement split products may be useful in determining the onset of disease and subsequent flares. Early identification and therapeutic intervention of patients at risk of a disease flare may reduce the frequency of their visits to doctors, reduce overall health care costs and improve the quality of their health."
 QUIDEL Corp. develops, manufactures and markets rapid immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, infectious diseases, allergy and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home testing markets.
 -0- 4/20/93 R
 /CONTACT: Scott L. Glenn, chairman and CEO, 619-552-7900, or Mark Francois, manager-investor relations, 619-552-7931, both of QUIDEL/
 (QDEL)


CO: QUIDEL Corp. ST: California IN: MTC SU: PDT

GK -- SD002R -- 7840 04/20/93 09:23 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1993
Words:456
Previous Article:MATLACK SYSTEMS, INC. REPORTS HIGHER REVENUE AND EARNINGS FOR THE SECOND FISCAL QUARTER
Next Article:SAFEWAY ANNOUNCES PRELIMINARY RESULTS FOR FIRST QUARTER OF 1993
Topics:


Related Articles
QUIDEL RECEIVES U.S PATENT WHICH WILL EXPAND ITS FERTILITY FRANCHISE
MERIDIAN RELEASES FOURTH PREMIER(TM) ENZYME IMMUNOASSAY
QUIDEL FORMS JOINT DISTRIBUTION VENTURE IN EUROPE
SYVA INTRODUCES NEW AUTOMATED IMMUNODIAGNOSTIC SYSTEM
QUIDEL'S NEW CONCEIVE(TM) ONE-STEP PREGNANCY TEST CLEARS FDA FOR HOME USE
QUIDEL REPORTS RECORD SALES FOR THE FOURTH QUARTER AND YEAR
QUIDEL AND BECTON DICKINSON SIGN NEW AGREEMENT - QUIDEL ACQUIRES RIGHTS TO CONSUMER FERTILITY PRODUCTS
QUIDEL REPORTS INCREASED SECOND QUARTER SALES; QUIDEL BRANDED PRODUCT SALES INCREASE 30 PERCENT
QUIDEL POSTS RECORD SALES AND PROFITABILITY FOR THIRD QUARTER
QUIDEL STARTS LARGE INFLUENZA RESEARCH PROGRAM IN COLLABORATION WITH GLAXO WELLCOME

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters